|
Aug 1
|
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
|
|
Aug 1
|
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
|
|
Jul 31
|
Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas
|
|
Jul 31
|
Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON
|
|
Jul 30
|
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
|
|
Jul 30
|
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
|
|
Jul 21
|
Why Alkermes Tumbled On Its Positive Narcolepsy Study
|
|
Jul 21
|
Takeda Pharmaceutical Receives FDA 510(k) Clearance for Hyqvia Devices
|
|
Jul 21
|
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
|
|
Jul 1
|
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
|
|
Jun 30
|
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 27
|
Will Strong Asceniv Sales Drive ADMA Biologics Further?
|
|
Jun 25
|
Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
|
|
Jun 25
|
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
|
|
Jun 25
|
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
|
|
Jun 25
|
Takeda Announces New Assignments of Directors
|
|
Jun 4
|
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
|
|
Jun 3
|
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
|
|
Jun 1
|
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
|